Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Value of Knowing: CMS Rejects Coverage of Lilly’s Amyvid – Except As Tool For Further Research

This article was originally published in RPM Report

Executive Summary

CMS is proposing to deny coverage of Lilly’s Alzheimer’s “rule-out” diagnostic Amyvid. The decision is important for biopharma manufacturers for several reasons, both as a demonstration that the agency really will refuse to pay for FDA approved drugs—and for how CMS thinks it can actually use its authority to encourage research on effective AD therapies.

Advertisement

Related Content

Alzheimer’s Community Prepares To Challenge CMS Amyvid Proposal
A New Direction for Alzheimer’s R&D: FDA Outlines Early Disease Pathway
CMS Proposed National Coverage Decision Topic List Exempts Biopharma
CMS Takes A Look At Alzheimer’s With Lilly's Amyvid In Mind
Coverage With Evidence Development and Expedited Approvals: Policy Proposals For FDA and CMS
What Will CMS Do With Avastin In Breast Cancer?
Medicare Will Cover Provenge Labeled Uses, CMS Proposes; Off-Label Is Up To Contractors
Dendreon vs. CMS:Controversy Is Bigger Than One Product
Relabeling EPO: Closing the Books on a Safety Issue, Opening a New Chapter at FDA
Living in a Bipolar World: Implications of the EPO Safety Debate (Part 1)

Topics

Advertisement
UsernamePublicRestriction

Register

PS081170

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel